Related Experiment Video

Updated: Jun 12, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Adjuvant therapy after R0 resection for primary hepatic sarcomatoid carcinoma

Takehiro Noji1,2, Toshimichi Asano1, Satoshi Hirano1

  • 1Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Japan.

Hepatobiliary Surgery and Nutrition
|June 11, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Adjuvant therapygenenomic landscape findingsprimary hepatic sarcomatoid

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Application of Hemostatic Devices in Laparoscopic Hepatectomy
04:23

Application of Hemostatic Devices in Laparoscopic Hepatectomy

Published on: April 19, 2022

Related Experiment Videos

Last Updated: Jun 12, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Application of Hemostatic Devices in Laparoscopic Hepatectomy
04:23

Application of Hemostatic Devices in Laparoscopic Hepatectomy

Published on: April 19, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

High CD73 Expression Is Associated with Poor Prognosis in Biliary Tract Cancer Through Reduced Stromal Tumor-Infiltrating Lymphocytes.

Cancers·2026

Comparable impact of lymph node metastases in T2 gallbladder cancer on postoperative prognosis irrespective of the extent of the metastases: A retrospective analysis.

Journal of hepato-biliary-pancreatic sciences·2025

Preoperative risk factors for skeletal muscle mass loss in patients with biliary tract cancer.

Journal of hepato-biliary-pancreatic sciences·2024

The degree of satisfaction and level of learning in male and female surgical residents: a nationwide questionnaire survey of graduating residents in Japan.

Surgery today·2023

Effect of gait training using Welwalk on gait pattern in individuals with hemiparetic stroke: a cross-sectional study.

Frontiers in neurorobotics·2023

Telesurgery and telesurgical support using a double-surgeon cockpit system allowing manipulation from two locations.

Surgical endoscopy·2023

Optimal timing of reoperation for postoperatively diagnosed T2 gallbladder cancer: a retrospective multicenter cohort study.

Hepatobiliary surgery and nutrition·2026

Liver donor macrosteatosis is associated with adverse long-term outcomes exclusively in metabolic dysfunction-associated steatotic liver disease recipients: a U.S. transplant registry analysis over the last decade.

Hepatobiliary surgery and nutrition·2026

When is enough enough?-predicting adequacy of portal vein embolization for hypertrophy of the future liver remnant in the age of liver venous deprivation.

Hepatobiliary surgery and nutrition·2026

Monitoring with plasma apolipoprotein A2-isoforms can predict developing new-onset steatotic liver disease caused by pancreatic exocrine insufficiency following pancreatectomy.

Hepatobiliary surgery and nutrition·2026

Diagnostic and management guidelines for biliary atresia in 2025.

Hepatobiliary surgery and nutrition·2026

Independent risk factors for clinically relevant postoperative pancreatic fistula after robotic pancreatoduodenectomy: the protective role of the modified Blumgart pancreatojejunostomy in a single surgeon retrospective cohort of 220 cases.

Hepatobiliary surgery and nutrition·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us